GSK Reports P-IV Trial (ZOSTER-076) Results of Shingrix (Recombinant Zoster Vaccine) for the Prevention of Shingles in Adults aged ≥50 Years in China
- The company highlighted the results from the post-license P-IV trial (ZOSTER-076) evaluating the efficacy and safety of RZV (administered as IM on a 2-dose schedule) vs PBO in a ratio (1:1) in 6000 patients aged ≥50yrs. for the prevention of shingles
- The results showed the vaccine efficacy of 97% over a follow-up period of ~4yrs. The results were consistent with the P-III trials (ZOE-50) and (ZOE-70) & the safety profile was consistent with the established safety profile of the vaccine
- Additionally, the results will be submitted for publication in a peer-reviewed scientific journal in 2023. Shingrix, a non-live, recombinant subunit vaccine indicated for the prevention of shingles in adults aged ≥50yrs.
Ref: GSK | Image: GSK
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.